Prospects for the use of anti-inflammatory therapy in patients with coronary artery disease

Coronary atherosclerosis is the primary cause of coronary artery disease, one of the world’s greatest causes of death. Inflammation plays a major role in atherosclerosis formation and progression. Cardiovascular disease risk factors such as dyslipidemia, hyperglycemia, smoking, hypertension and others contribute to endothelial injury. This sets off a cascade of inflammatory reactions accompanied by the release of cytokines and other inflammatory mediators, ultimately leading to rupture or erosion of the atherosclerotic plaque and atherothrombosis. Large studies such as CANTOS (Canakinumab Anti-Inflammatory Thrombosis Outcomes Study); COLCOT (Colchicine Cardiovascular Outcomes Trial) and LoDoCo2 (Low Dose Colchicine 2) demonstrated that the use of anti-inflammatory drugs improves the prognosis of patients with coronary atherosclerosis. At present, the most convincing evidence of the effectiveness of anti-inflammatory therapy was obtained only for colchicine and canakinumab. However, despite these promising results, there are still many issues to be addressed. Firstly, more research is needed to determine the optimal dosage and duration of these drugs. Secondly, the safety of their prolonged use should be carefully assessed, especially in the context of possible side effects. For example, anti-inflammatory drugs can potentially pose infectious risks that require special monitoring and follow-up. The review presents current views on the possibilities immunomodulatory drugs using in the complex treatment of atherosclerosis.

1. Mach F, Baigent C, Catapano AL, et al; ESC Scientific Document Group. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41(1):111-88. DOI: 10.1093/eurheartj/ehz455.

2. 2020 Clinical practice guidelines for Stable coronary artery disease. Russian Journal of Cardiology. 2020;25(11):4076 (In Russ.) DOI: 10.15829/1560-4071-2020-4076.

3. Aukrust P, Halvorsen B, Yndestad A, et al. Chemokines and cardiovascular risk. Arterioscler Thromb Vasc Biol. 2008;28(11):1909-19. DOI: 10.1161/ATVBAHA.107.161240.

4. Eniseeva ES, Protasov KV. Colchicine in patients with coronary heart disease: new possibilities in reduction of the residual inflammatory risk. Siberian Medical Review. 2021;(6):12-21. (In Russ.) DOI: 10.20333/25000136-2021-6-12-21.

5. Imazio M, Nidorf M. Colchicine and the heart. Eur Heart J. 2021;42(28):2745-60. DOI: 10.1093/eurheartj/ehab221.

6. Li Y, Zhang Y, Lu J, et al. Anti-inflammatory mechanisms and research progress of colchicine in atherosclerotic therapy. J Cell Mol Med. 2021;25(17):8087-94. DOI: 10.1111/jcmm.16798.

7. Karasawa T, Takahashi M. Role of NLRP3 inflammasomes in atherosclerosis. J Atheroscler Thromb. 2017;24(5):443-51. DOI: 10.5551/jat.RV17001.

8. Abduzhamalova NM, Karpov AM, Naumov VG. Modern concepts about the role of inflammation in atherosclerosis pathogenesis. Тherapist. 2015;(4):57-61 (In Russ.)

9. Schwartz RS, Bayes-Genis A, Lesser JR, et al. Detecting vulnerable plaque using peripheral blood: inflammatory and cellular markers. J Interv Cardiol. 2003;16(3):231-42. DOI: 10.1034/j.1600-0854.2003.8025.x.

10. Ridker PM, Bhatt DL, Pradhan AD, et al; PROMINENT, REDUCE-IT, and STRENGTH Investigators. Inflammation and cholesterol as predictors of cardiovascular events among patients receiving statin therapy: a collaborative analysis of three randomised trials. Lancet. 2023;401(10384):1293-301. DOI: 10.1016/S0140-6736(23)00215-5.

11. Pasceri V, Yeh ET. A tale of two diseases: atherosclerosis and rheumatoid arthritis. Circulation. 1999;100(21):2124-6. DOI: 10.1161/01.cir.100.21.2124.

12. Nasonov EL, Popkova TV. Role of interleukin 1 in the development of atherosclerosis. Rheumatology Science and Practice. 2018;56(Suppl 4):28-34 (In Russ.) DOI: 10.14412/1995-4484-2018-28-34.

13. Ramírez Huaranga MA, Mínguez Sánchez MD, Zarca Díaz de la Espina MÁ, et al. What role does rheumatoid arthritis disease activity have in cardiovascular risk? Reumatol Clin (Engl Ed). 2018;14(6):339-45. DOI: 10.1016/j.reuma.2017.03.013.

14. Maradit-Kremers H, Crowson CS, Nicola PJ, et al. Increased unrecognized coronary heart disease and sudden deaths in rheumatoid arthritis: a population-based cohort study. Arthritis Rheum. 2005;52(2):402-11. DOI: 10.1002/art.20853.

15. Aubry MC, Maradit-Kremers H, Reinalda MS, et al. Differences in atherosclerotic coronary heart disease between subjects with and without rheumatoid arthritis. J Rheumatol. 2007;34(5):937-42.

16. Bedeković D, Bošnjak I, Bilić-Ćurčić I, et al. Risk for cardiovascular disease development in rheumatoid arthritis. BMC Cardiovasc Disord. 2024;24(1):291. DOI: 10.1186/s12872-024-03963-3.

17. Alexeeva E, Shingarova M, Dvoryakovskaya T, et al. Safety and efficacy of canakinumab treatment for undifferentiated autoinflammatory diseases: the data of a retrospective cohort two-centered study. Front Med (Lausanne). 2023;10:1257045. DOI: 10.3389/fmed.2023.1257045.

18. Nguyen MT, Fernando S, Schwarz N, et al. Inflammation as a Therapeutic Target in Atherosclerosis. J Clin Med. 2019;8(8):1109. DOI: 10.3390/jcm8081109.

19. Ridker PM, Everett BM, Thuren T, et al; CANTOS Trial Group. Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease. N Engl J Med. 2017;377(12):1119-31. DOI: 10.1056/NEJMoa1707914.

20. Andreotti F, Maggioni AP, Campeggi A, et al. Anti-inflammatory therapy in ischaemic heart disease: from canakinumab to colchicine. Eur Heart J Suppl. 2021;23(Suppl E):E13-E18. DOI: 10.1093/eurheartj/suab084.

21. Ridker PM, Everett BM, Pradhan A, et al; CIRT Investigators. Low-Dose Methotrexate for the Prevention of Atherosclerotic Events. N Engl J Med. 2019;380(8):752-62. doi: 10.1056/NEJMoa1809798.

22. Naranjo A, Sokka T, Descalzo MA, et al; QUEST-RA Group. Cardiovascular disease in patients with rheumatoid arthritis: results from the QUEST-RA study. Arthritis Res Ther. 2008;10(2):R30. DOI: 10.1186/ar2383.

23. Samuel M, Tardif JC. Lessons learned from large Cardiovascular Outcome Trials targeting inflammation in cardiovascular disease (CANTOS, CIRT, COLCOT and LoDoCo2). Future Cardiol. 2021;17(3):411-4. DOI: 10.2217/fca-2021-0027.

24. Chen T, Liu G, Yu B. Colchicine for Coronary Artery Disease: A Review. Front Cardiovasc Med. 2022:9:892588. DOI: 10.3389/fcvm.2022.892588.

25. Kofler T, Kurmann R, Lehnick D, et al. Colchicine in Patients With Coronary Artery Disease: A Systematic Review and Meta-Analysis of Randomized Trials. J Am Heart Assoc. 2021;10(16):e021198. DOI: 10.1161/JAHA.121.021198.

26. Martínez GJ, Robertson S, Barraclough J, et al. Colchicine acutely suppresses local cardiac production of inflammatory cytokines in patients with an acute coronary syndrome. J Am Heart Assoc. 2015;4(8):e002128. DOI: 10.1161/JAHA.115.002128.

27. Fiolet ATL, Silvis MJM, Opstal TSJ, et al. Short-term effect of low-dose colchicine on inflammatory biomarkers, lipids, blood count and renal function in chronic coronary artery disease and elevated high-sensitivity C-reactive protein. PLoS One. 2020;15(8):e0237665. DOI: 10.1371/journal.pone.0237665.

28. Nidorf M, Thompson PL. Effect of colchicine (0.5 mg twice daily) on highsensitivity C-reactive protein independent of aspirin and atorvastatin in patients with stable coronary artery disease. Am J Cardiol. 2007;99(6):805-7. DOI: 10.1016/j.amjcard.2006.10.039.

29. Opstal TSJ, Hoogeveen RM, Fiolet ATL, et al. Colchicine Attenuates Inflammation Beyond the Inflammasome in Chronic Coronary Artery Disease. A LoDoCo2 Proteomic Substudy. Circulation. 2020;142(20):1996–8. DOI: 1161/CIRCULATIONAHA.120.050560.

30. Zhou Y, Liu Y, Zeng R, et al. Early long-term low-dosage colchicine and major adverse cardiovascular events in patients with acute myocardial infarction: a systematic review and meta-analysis. Front Cardiovasc Med. 2023;10:1194605. DOI: 10.3389/fcvm.2023.1194605.

31. Cecconi A, Vilchez-Tschischke JP, Mateo J, et al. Effects of Colchicine on Atherosclerotic Plaque Stabilization: a Multimodality Imaging Study in an Animal Model. J Cardiovasc Transl Res. 2021;14(1):150-60. DOI: 10.1007/s12265-020-09974-7.

32. Li W, Lin A, Hutton M, et al. Colchicine promotes atherosclerotic plaque stability independently of inflammation. bioRxiv [Preprint]. 2023:2023.10.03.560632. DOI: 10.1101/2023.10.03.560632.

33. Schwarz N, Fernando S, Chen YC, et al. Colchicine exerts anti-atherosclerotic and -plaque-stabilizing effects targeting foam cell formation. FASEB J. 2023;37(4):e22846. DOI: 10.1096/fj.202201469R.

34. Vaidya K, Arnott C, Martínez GJ, et al. Colchicine Therapy and Plaque Stabilization in Patients With Acute Coronary Syndrome: A CT Coronary Angiography Study. JACC Cardiovasc Imaging. 2018;11(2 Pt 2):305-16. DOI: 10.1016/j.jcmg.2017.08.013.

35. Nidorf SM, Eikelboom JW, Budgeon CA, Thompson PL. Low-dose colchicine for secondary prevention of cardiovascular disease. J Am Coll Cardiol. 2013;61(4):404-10. DOI: 10.1016/j.jacc.2012.10.027.

36. Tardif JC, Kouz S, Waters DD, et al. Efficacy and Safety of Low-Dose Colchicine after Myocardial Infarction. N Engl J Med. 2019;381(26):2497-505. DOI: 10.1056/NEJMoa1912388.

37. Nidorf SM, Fiolet ATL, Mosterd A, et al; LoDoCo2 Trial Investigators. Colchicine in Patients with Chronic Coronary Disease. N Engl J Med. 2020;383(19):1838-47. DOI: 10.1056/NEJMoa2021372.

38. Liuzzo G, Patrono C. Low-dose colchicine: a new tool in the treatment of chronic coronary disease? Comment on the low-dose colchicine (LoDoCo)2 trial. Eur Heart J. 2020;41(40):3880-1. DOI: 10.1093/eurheartj/ehaa782.

39. Mamedov МN, Kanorsky SG. International clinical research in cardiology (2010-2023). M.: Cardioprogress; 2024 (In Russ.).

40. Akl E, Sahami N, Labos C, et al. Meta-Analysis of Randomized Trials: Efficacy and Safety of Colchicine for Secondary Prevention of Cardiovascular Disease. J Interv Cardiol. 2024;2024:8646351. DOI: 10.1155/2024/8646351.

41. Bytyçi I, Bajraktari G, Penson PE, et al; Lipid and Blood Pressure Meta-Analysis Collaboration (LBPMC) Group; International Lipid Expert Panel (ILEP). Efficacy and safety of colchicine in patients with coronary artery disease: A systematic review and meta-analysis of randomized controlled trials. Br J Clin Pharmacol. 2022;88(4):1520-8. DOI:10.1111/bcp.15041.

42. Banach M, Penson PE. Colchicine and Cardiovascular Outcomes: a Critical Appraisal of Recent Studies. Curr Atheroscler Rep. 2021;23(7):32. DOI: 10.1007/s11883-021-00932-5.

43. Tong DC, Quinn S, Nasis A, et al. Colchicine in Patients With Acute Coronary Syndrome: The Australian COPS Randomized Clinical Trial. Circulation. 2020;142(20):1890-900. DOI: 10.1161/CIRCULATIONAHA.120.050771.

44. van Broekhoven A, Mohammadnia N, Silvis MJM, et al. The Effect of Years-Long Exposure to Low-Dose Colchicine on Renal and Liver Function and Blood Creatine Kinase Levels: Safety Insights from the Low-Dose Colchicine 2 (LoDoCo2) Trial. Clin Drug Investig. 2022;42(11):977-85. DOI: 10.1007/s40261-022-01209-8.

45. Nidorf SM, Ben-Chetrit E, Ridker PM. Low-dose colchicine for atherosclerosis: long-term safety. Eur Heart J. 2024;45(18):1596-1601. DOI: 10.1093/eurheartj/ehae208.

46. Andreis A, Imazio M, Avondo S, et al. Adverse events of colchicine for cardiovascular diseases: a comprehensive meta-analysis of 14 188 patients from 21 randomized controlled trials. J Cardiovasc Med (Hagerstown). 2021;22(8):637–44. DOI: 10.2459/JCM.0000000000001157.

47. Wiggins BS, Saseen JJ, Page RL, et al; American Heart Association Clinical Pharmacology Committee of the Council on Clinical Cardiology; Council on Hypertension; Council on Quality of Care and Outcomes Research; and Council on Functional Genomics and Translational Biology. Recommendations for management of clinically significant drug-drug interactions with statins and select agents used in patients with cardiovascular disease: a scientific statement from the American Heart Association. Circulation. 2016;134(21):e468–e495. DOI: 10.1161/CIR.0000000000000456.

48. Visseren FLJ, Mach F, Smulders YM, et al. ESC National Cardiac Societies; ESC Scientific Document Group. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021;42(34):3227-37. DOI: 10.1093/eurheartj/ehab484.

49. Aldana-Bitar J, Golub IS, Moore J, et al. Colchicine and plaque: A focus on atherosclerosis imaging. Prog Cardiovasc Dis. 2024:84:68-75. DOI: 10.1016/j.pcad.2024.02.010.

50. Nidorf SM. Seeing Colchicine in a New Light: Repurposing Low-dose Colchicine for Secondary Prevention of Cardiovascular Disease. Clin Ther. 2023;45(11):1029-33. DOI: 10.1016/j.clinthera.2023.07.007.

51. Virani SS, Newby LK, Arnold SV, et al; Peer Review Committee Members. 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines. 2023;148(9):e9-e119. DOI: 10.1161/CIR.0000000000001168.

52. Vrints C, Andreotti F, Koskinas KC, et al; ESC Scientific Document Group. 2024 ESC Guidelines for the management of chronic coronary syndromes. Eur Heart J. 2024;29;45(36):3415-37. DOI: 10.1093/eurheartj/ehae177.

53. Moras E, Subramanian L, Romeo F, et al. Role of Colchicine in Cardiovascular Disorders. Cardiol Rev. 2024. DOI:10.1097/CRD.0000000000000723. Online ahead of print.